본문 바로가기
KERD
논문KCI 등재

A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective

Moran Ki|Sook-Hyang Jeong|Eun Sun Jang|Kyung-Ah Kim|김혜린|Gwang Hyun Choi|Hwa Young Choi
대한간학회 (The korean Association for the Study of the Liver)|2022.01|Clinical and Molecular Hepatology|제28권 제1호|pp. 91-104|DOI 10.3350/cmh.2021.0236

2

조회

0

다운로드

6

인용

0

참고문헌

키워드

Hepatitis C virusCost effectivenessMass screeningsQuality adjusted life years

초록

Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published decision-tree plus Markov model was used to compare the expected costs and quality-adjusted life years (QALY) between one-time universal HCV screening and no screening in the population aged 40–65 years using the National Health Examination (NHE) program. Input parameters were obtained from analyses of the National Health Insurance claims data, Korean HCV cohort data, or from the literature review. The population aged 40–65 years was simulated in a model spanning a lifetime from both the healthcare system and societal perspectives, which included the cost of productivity loss due to HCV-related deaths. The incremental cost-effectiveness ratio (ICER) between universal screening and no screening was estimated. Results: The HCV screening strategy had an ICER of $2,666/QALY and $431/QALY from the healthcare system and societal perspectives, respectively. Both ICERs were far less than the willingness-to-pay threshold of $25,000/QALY, showing that universal screening was highly cost-effective compared to no screening. In various sensitivity analyses, the most influential parameters on cost-effectiveness were the antibodies to HCV (anti-HCV) prevalence, screening costs, and treatment acceptance; however, all ICERs were consistently less than the threshold. If the anti-HCV prevalence was over 0.18%, screening could be cost-effective. Conclusions: One-time universal HCV screening in the Korean population aged 40–65 years using NHE program would be highly cost-effective from both healthcare system and societal perspectives.

Abstract

Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published decision-tree plus Markov model was used to compare the expected costs and quality-adjusted life years (QALY) between one-time universal HCV screening and no screening in the population aged 40–65 years using the National Health Examination (NHE) program. Input parameters were obtained from analyses of the National Health Insurance claims data, Korean HCV cohort data, or from the literature review. The population aged 40–65 years was simulated in a model spanning a lifetime from both the healthcare system and societal perspectives, which included the cost of productivity loss due to HCV-related deaths. The incremental cost-effectiveness ratio (ICER) between universal screening and no screening was estimated. Results: The HCV screening strategy had an ICER of $2,666/QALY and $431/QALY from the healthcare system and societal perspectives, respectively. Both ICERs were far less than the willingness-to-pay threshold of $25,000/QALY, showing that universal screening was highly cost-effective compared to no screening. In various sensitivity analyses, the most influential parameters on cost-effectiveness were the antibodies to HCV (anti-HCV) prevalence, screening costs, and treatment acceptance; however, all ICERs were consistently less than the threshold. If the anti-HCV prevalence was over 0.18%, screening could be cost-effective. Conclusions: One-time universal HCV screening in the Korean population aged 40–65 years using NHE program would be highly cost-effective from both healthcare system and societal perspectives.

참고문헌 (45)

  1. "Interim guidance for country validation of viral hepatitis elimination"[URL]
  2. "Global hepatitis report 2017"[URL]
  3. "Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection"[URL]
  4. Backus LI, "Direct-acting antiviral sustained virologic response : impact on mortality in patients without advanced liver disease", Hepatology, 68, pp.827~838 (2018)
  5. Backus LI, "Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease", Hepatology, 69, pp.487~497 (2019)
  6. Jang ES, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatol Int, 13, pp.599~608 (2019)
  7. "Framework Act on Health Examinations"[URL]
  8. Kim DY, "Costeffectiveness of increased screening and treatment of chronic hepatitis C in Korea", Curr Med Res Opin, 36, pp.993~1002 (2020)
  9. Kim KA, "Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population", Liver Int, 39, pp.60~69 (2019)
  10. Kim DY, "Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea", PLoS One, 12, pp.e0167770~ (2017)
  11. Marc G. Ghany, "Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection", Hepatology, 71(2), pp.686~721 (2020), Ovid Technologies (Wolters Kluwer Health)[DOI]
  12. "2017 KASL clinical practice guidelines management of hepatitis C: treatment of chronic hepatitis C"[URL]
  13. "The pharmacoeconomic evaluation guideline (2021.1)" (2021)[URL]
  14. National Health Insurance Service (NHIS), "National Health Statistical Yearbook", National Health Insurance Service, ~ (2019)
  15. 이치훈, "Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody", Clinical and Molecular Hepatology, 19(4), pp.376~381 (2013), 대한간학회[DOI]
  16. "Resident registration age population by city/county/sex/age (age 1 year old)"[URL]
  17. Eun Sun Jang, "Effectiveness and safety of elbasvir", grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study, 2021, pp.36, 1~8[DOI]
  18. "Statistics of Infectious Disease"[URL]
  19. Jang Eun Sun, "Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose", Gut and Liver, 14(6), pp.775~782 (2020), 거트앤리버 소화기연관학회협의회[DOI]
  20. Kwon JH, "Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens : a multicenter study in Korea", J Med Virol, 91, pp.1104~1111 (2019)
  21. Nozaki A, "The effectiveness and safety of glecaprevir", pibrentasvir in chronic hepatitis C patients with refractory factors in the real world : a comprehensive analysis of a prospective multicenter study, 2020, pp.14, 225~238
  22. Park Young Joo, "Real-Life Effectiveness and Safety of Glecaprevir", Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution, 2021, pp.15(3), 440~450[DOI]
  23. Coffin PO, "Cost-effectiveness and population outcomes of general population screening for hepatitis C", Clin Infect Dis, 54, pp.1259~1271 (2012)
  24. Dienstag JL, "A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C", Hepatology, 54, pp.396~405 (2011)
  25. Erman A, "Estimation of fibrosis progression rates for chronic hepatitis C : a systematic review and meta-analysis update", BMJ Open, 9, pp.e027491~ (2019)
  26. Igarashi A, "Cost-utility analysis of sofosbuvir for the treatment of genotype 2chronic hepatitis C in Japan", Curr Med Res Opin, 33, pp.1~10 (2017)
  27. Imazeki F, "Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C", Liver Int, 25, pp.772~778 (2005)
  28. 김종만, "Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study", Annals of Surgical Treatment and Research, 90(1), pp.36~42 (2016), 대한외과학회
  29. Krauth C, "Elimination of hepatitis C virus in Germany : modelling the cost-effectiveness of HCV screening strategies", BMC Infect Dis, 19, pp.1019~ (2019)
  30. Lee SS, "Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea", J Gastroenterol Hepatol, 30, pp.1281~1287 (2015)
  31. Mattingly TJ 2nd, "Value in hepatitis C virus treatment : a patient-centered cost-effectiveness analysis", Pharmacoeconomics, 38, pp.233~242 (2020)
  32. Nakamura J, "Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups", Tohoku J Exp Med, 215, pp.33~42 (2008)
  33. Sinn DH, "Comparison of clinical manifestations and outcomes between hepatitis B virus-and hepatitis C virus-related hepatocellular carcinoma : analysis of a nationwide cohort", PLoS One, 9, pp.e112184~ (2014)
  34. "2019 Complete Life Table (by Age)"[URL]
  35. Sanders GD, "Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses : second panel on costeffectiveness in health and medicine", JAMA, 316, pp.1093~1103 (2016)
  36. Kim DD, "Perspective and costing in cost-effectiveness analysis, 1974-2018", Pharmacoeconomics, 38, pp.1135~1145 (2020)
  37. Deuffic-Burban S, "Assessing the cost-effectiveness of hepatitis C screening strategies in France", J Hepatol, 69, pp.785~792 (2018)
  38. Eckman MH, "Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens", Clin Gastroenterol Hepatol, 17, pp.930~939 (2019)
  39. Nagai K, "Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan", Hepatol Res, 50, pp.542~556 (2020)
  40. Geue C, "Cost-effectiveness of HBV and HCV screening strategies--a systematic review of existing modelling techniques", PLoS One, 10, pp.e0145022~ (2015)
  41. "Currently Applied Drug Price File"[URL]
  42. Pitman R, "Dynamic transmission modeling : a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5", Med Decis Making, 32, pp.712~721 (2012)
  43. "Raw data of 2018 (KNHANES VII, 2018)"[URL]
  44. Abdel-Hamid M, "Comparison of second-and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus", J Clin Microbiol, 40, pp.1656~1659 (2002)
  45. Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회

이 간행물의 다른 논문 (10건)

The management of post-transplantation recurrence of hepatocellular carcinomaMarco PAW Claasen, Hala Muaddi, Gonzalo Sapisochin, Luckshi Rajendran, Tommy Ivanicspp. 1-16Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virusJun Sik Yoon, 이민종, Yuri Cho, Sun Woong Kimpp. 17-30Current knowledge about biomarkers of acute kidney injury in liver cirrhosisYeon Seok Seo, Han Ah Leepp. 31-46Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?Seung Mi Lee, 김원pp. 47-49Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment권자영pp. 50-51
원문 보기